Market Overview

Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

Related KERX
Keryx Biopharma Reports Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting
Good News for Keryx - Analyst Blog

In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX).

Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.”

Keryx Biopharmaceuticals closed on Tuesday at $2.93.

Posted-In: Dawson James SecuritiesAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (KERX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free